<h3>享受 TipRanks 高级版 50% 折扣，安心投资</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
<p>Humacyte（HUMA）的公告现已发布。</p>
<p>2025 年 12 月 16 日，Humacyte, Inc.与 TD Securities (USA) LLC 签订了销售协议，提供和出售其普通股，累计发行价格最高可达 6000 万美元。此次发行的收益旨在支持 Symvess®在血管创伤方面的商业化、进一步开发 Humacyte 的产品管线以及一般企业用途。该协议允许 TD Cowen 通过多种方式出售股票，包括市场发行，并包括在特定条件下终止的条款。公司已同意向 TD Cowen 支付佣金，并在协议中作出了惯例的陈述和保证。</p>
<p>（HUMA）股票的最新分析师评级为买入，目标价格为 3.00 美元。要查看 Humacyte 股票的完整分析师预测列表，请访问 HUMA 股票预测页面。</p>
<p><strong>Spark 对 HUMA 股票的看法</strong></p>
<p>根据 Spark，TipRanks 的人工智能分析师，HUMA 的评级为中性。</p>
<p>Humacyte 的整体股票评分反映出显著的财务和技术挑战。缺乏收入、持续亏损和负资产严重影响财务表现。技术分析显示出看跌动能。估值指标表明，考虑到负的市盈率和缺乏股息，该股票可能被高估。尽管收益电话会议对未来增长提供了一些乐观预期，因 FDA 批准和产品发布，但这些都是在当前财务困难下的长期前景。最近的公司事件发出混合信号，存在潜在的法律风险和成功的资本募集。</p>
<p>要查看 Spark 关于 HUMA 股票的完整报告，请点击这里。</p>
<p><strong>关于 Humacyte 的更多信息</strong></p>
<p>Humacyte, Inc.在生物技术行业运营，专注于生物工程人类组织的开发和商业化。该公司特别致力于为血管创伤创造产品，并拥有一系列旨在满足各种医疗需求的产品候选。</p>
<p><strong>平均交易量：</strong> 5,428,726</p>
<p><strong>技术情绪信号：</strong> 卖出</p>
<p><strong>当前市值：</strong> 2.453 亿美元</p>
<p>要全面评估 HUMA 股票，请访问 TipRanks 的股票分析页面。</p>

HUMA

<p>Humacyte, Inc. 宣布与 TD Securities 签署了一项销售协议，出售最多 6000 万美元的普通股。所得款项将用于支持 Symvess® 的商业化、产品管道开发和公司用途。TD Cowen 将通过多种方式出售股票，包括市场发行。该协议包括佣金支付和终止条款。分析师对 HUMA 股票的评级为买入，目标价为 3.00 美元，但 Spark 的 AI 分析师由于财务挑战和看跌的技术分析，将其视为中性</p>

<h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>享受 TipRanks 高级版 50% 折扣，安心投资</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
</div><p>An announcement from Humacyte ( (HUMA) ) is now available.</p>
<div class="lb-trans"><p>Humacyte（HUMA）的公告现已发布。</p>
</div><p>On December 16, 2025, Humacyte, Inc. entered into a Sales Agreement with TD Securities (USA) LLC to offer and sell its common stock, with an aggregate offering price of up to $60 million. The proceeds from this offering are intended to support the commercialization of Symvess® for vascular trauma, further development of Humacyte’s product pipeline, and general corporate purposes. The agreement allows TD Cowen to sell shares through various methods, including at-the-market offerings, and includes provisions for termination under specific conditions. The company has agreed to pay a commission to TD Cowen and has made customary representations and warranties as part of the agreement.</p>
<div class="lb-trans"><p>2025 年 12 月 16 日，Humacyte, Inc.与 TD Securities (USA) LLC 签订了销售协议，提供和出售其普通股，累计发行价格最高可达 6000 万美元。此次发行的收益旨在支持 Symvess®在血管创伤方面的商业化、进一步开发 Humacyte 的产品管线以及一般企业用途。该协议允许 TD Cowen 通过多种方式出售股票，包括市场发行，并包括在特定条件下终止的条款。公司已同意向 TD Cowen 支付佣金，并在协议中作出了惯例的陈述和保证。</p>
</div><p>The most recent analyst rating on (HUMA) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Humacyte stock, see the HUMA Stock Forecast page.</p>
<div class="lb-trans"><p>（HUMA）股票的最新分析师评级为买入，目标价格为 3.00 美元。要查看 Humacyte 股票的完整分析师预测列表，请访问 HUMA 股票预测页面。</p>
</div><p><strong>Spark’s Take on HUMA Stock</strong></p>
<div class="lb-trans"><p><strong>Spark 对 HUMA 股票的看法</strong></p>
</div><p>According to Spark, TipRanks’ AI Analyst, HUMA is a Neutral.</p>
<div class="lb-trans"><p>根据 Spark，TipRanks 的人工智能分析师，HUMA 的评级为中性。</p>
</div><p>Humacyte’s overall stock score reflects significant financial and technical challenges. The lack of revenue, persistent losses, and negative equity weigh heavily on the financial performance. Technical analysis indicates bearish momentum. The valuation metrics suggest the stock may be overpriced given the negative P/E ratio and absence of dividends. The earnings call offered some optimism regarding future growth due to FDA approvals and product launches, but these are long-term prospects amid current financial difficulties. Recent corporate events provide mixed signals with potential legal risks and a successful capital raise.</p>
<div class="lb-trans"><p>Humacyte 的整体股票评分反映出显著的财务和技术挑战。缺乏收入、持续亏损和负资产严重影响财务表现。技术分析显示出看跌动能。估值指标表明，考虑到负的市盈率和缺乏股息，该股票可能被高估。尽管收益电话会议对未来增长提供了一些乐观预期，因 FDA 批准和产品发布，但这些都是在当前财务困难下的长期前景。最近的公司事件发出混合信号，存在潜在的法律风险和成功的资本募集。</p>
</div><p>To see Spark’s full report on HUMA stock, click here.</p>
<div class="lb-trans"><p>要查看 Spark 关于 HUMA 股票的完整报告，请点击这里。</p>
</div><p><strong>More about Humacyte</strong></p>
<div class="lb-trans"><p><strong>关于 Humacyte 的更多信息</strong></p>
</div><p>Humacyte, Inc. operates in the biotechnology industry, focusing on the development and commercialization of bioengineered human tissue. The company is particularly involved in creating products for vascular trauma and has a pipeline of product candidates aimed at addressing various medical needs.</p>
<div class="lb-trans"><p>Humacyte, Inc.在生物技术行业运营，专注于生物工程人类组织的开发和商业化。该公司特别致力于为血管创伤创造产品，并拥有一系列旨在满足各种医疗需求的产品候选。</p>
</div><p><strong>Average Trading Volume:</strong> 5,428,726</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 5,428,726</p>
</div><p><strong>Technical Sentiment Signal:</strong> Sell</p>
<div class="lb-trans"><p><strong>技术情绪信号：</strong> 卖出</p>
</div><p><strong>Current Market Cap:</strong> $245.3M</p>
<div class="lb-trans"><p><strong>当前市值：</strong> 2.453 亿美元</p>
</div><p>For a thorough assessment of HUMA stock, go to TipRanks’ Stock Analysis page.</p>
<div class="lb-trans"><p>要全面评估 HUMA 股票，请访问 TipRanks 的股票分析页面。</p>
</div>

Humacyte 与 TD 证券签署销售协议